Skip to main content

Advertisement

Table 3 Comparison of GLP-1 analogues in DPP-4 inhibitors- data from fully published RCTs [3335, 37].

From: Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus

Study The 1860- Lira DPP-4 study (52 weeks) DURATION 2 (26 weeks) - Add on therapy to Metformin DURATION 4 (26 weeks) - Monotherapy
Agent Liraglutide .8 mg/day Liraglutide1.2 mg/day Sitagliptin100 mg/day Exenatide QW2 mg/weekly Sitagliptin100 mg/day Exenatide QW2 mg/weekly Sitagliptin100 mg/day
Number of patients 225 221 219 160 166 248 163
Mean baseline HbA1c (%) 8.4 (0.8) 8.4 (0.7) 8.5 (0.7) 8.6 (1.2) 8.5 (1.2) 8.4-8.6 8.4-8.6
Change in HbA1c (%) -1.51 -1.29 -0.88 -1.5 -0.9 -1.53 -1.15 (P =<0.001)
Mean treatment difference in HbA1c with DPP-4 inhibitor -0.63 (P <0.0001) -0.4 (P <0.0001) - -0.6 (P <0.0001) - - -
Mean baseline FPG (mmol/L) 10.1 (2.4) 9.9(2.4) 10.0 (2.0) 9.2(2.9) 9.1(2.5) 9.7 to 9.9 9.7 to 9.9
Change in FPG (mmol/L) -2.04 -1.71 -0.59 -1.8 -0.9 -2.3 -1.1 (P =<0.001)
Mean treatment difference in FPG with DPP-4 inhibitor -1.45 (P <0.0001) -1.13 (P <0.0001) - -0.9 (P <0.0001) - - -
Baseline weight (Kg) 93.7(18.4) 94.6(18.1) 93.1(18.9) 89(20) 87(20) 85.9 to 88.6 85.9 to 88.6
Change in weight (Kg) -3.68 -2.78 -1.16 -2.3 -0.8 -2.0 -0.8 (P <0.001)
Mean treatment differences in weight with DPP-4 inhibitor -2.53 (P <0.0001) -1.62 (P <0.0001) - -1.5 (P <0.0001) - - -
Incidence of hypoglycemia 0.143episodes/ patient/year 0.154 episodes/ patient/year 0.137 episodes/ patient/year 1% 3% 5.2% 3.1%
Nausea Number (%) 60 (27.5) 40 (21.7) 12 (5.5) 38 (24) 16 (10) 11.3% 3.7%
Diarrhea Number (%) 27 (12.4) 20 (9) 14 (6.4) 29 (18) 16 (10) 10.9% 5.5%
  1. DDP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobulin A1c